A participant died in a clinical trial of a U.S. Food and Drug Administration (FDA)-approved antibody treatment for Alzheimer’s disease, and the death may be linked to the drug, a new case report reveals.
The case, published in May in the Journal of Alzheimer’s Disease, details unreported adverse outcomes associated with the use of lecanemab (Lequembi), an anti-amyloid plaque therapy intended to slow disease progression.
